announcement - lehman to present at biox , page-21

Tomorrow morning's PRR Biox presentation is a panel event:

"September 24, 2012, 5:50pm - UCONN Stamford Campus, Main Meeting / Lecture Hall

Innovation in Immunotherapy and Vaccines.
Dr. Phil Greenberg, Fred Hutchinson Cancer Centre.

Immunotherapy has made steady progress in recent years and the industry has seen a revival of interest in the development of therapeutic and preventative vaccine. However, investors and Big Pharma are looking for more concrete progress that mitigates risk, a natural ally of innovation. The most notable progress, as measured by commercial approval, may be in the area of therapeutic vaccines for cancer - from the approval of the first dendritic cell therapy (Provenge for hormone resistant prostate cancer in 2010) to the approval of a CTLA-4 blocker (Yervoy for metastatic melanoma in 2011). Some of the most exciting immunotherapy innovation may be related to progress in synthetic biology and DNA based vaccines for preventative as well as therapeutic approaches.

The panel will also discuss the significance of delivery of DNA vaccines by electroporation or viral vectors. Historically, vaccines have been proficient at inducing an antibody response (B-cells, humoral) but lacking in developing an antigen driven T-cell response that is crucial for most viral infections or cancer (in the case of therapeutic vaccines). In addition, the role of toll-like receptors (TLRs), another of area of promise in vaccine development, will be addressed.

Needless to say, many investors see significant risk and uncertainty in immunotherapy and vaccine development - additional commercial success and data points are needed for investors to embrace innovation in immunotherapy and vaccine pipelines. The panel will include corporate scientists and key opinion leaders from industry and academia and will aim to assess the state of innovation in the industry as well as the clinical and regulatory challenges that are of concern to investors.”

A G E N D A
"Monday, September 24, 2012:
5:55pm, Panel Presentation - Innovation in Immunotherapy & Vaccines

Moderator - Rahul Jasuja, Ph.D., Managing Director, Biotechnology Research, Noble Financial Capital Markets

KOL Dr. Phil Greenberg, Head of the Program in Immunology at the Fred Hutchinson Cancer Research Center

Inovio: Joseph Kim, Ph.D., CEO
Galena: Mark Ahn, Ph.D., CEO
Argos: Charles Nicolette, Ph.D., Chief Scientific Officer
Prima Biomed: Neil Frazer, M.D., Chief Medical Officer
Newlink Genetics: Charles Link, M.D., Chief Scientific Officer"

This bit interests me: "Historically, vaccines have been proficient at inducing an antibody response ......... but lacking in developing an antigen driven T-cell response that is crucial for most viral infections or cancer (in the case of therapeutic vaccines)."

Cue the ICS data!

Good luck all. Herro